Actos Medical Library

All Documents

  • Achanzar 2007 – Urine acidification has no effect on PPAR singaling or EGF expression  :LOAD Full PDF

  • Alberg-Cig Smoking and BladderCancer-Trends  :LOAD Full PDF

  • Baris2009-A case-control study of smoking and bladder cancer risk_emergent patterns over time.  :LOAD Full PDF

  • Begum 2002 – Expression of PPARy and the growth inhibitory effect  :LOAD Full PDF

  • Boffetta2008-Tobacco smoking and risk of bladder cancer  :LOAD Full PDF

  • Burin 1995 – Human Bladder Cancer  :LOAD Full PDF

  • Burstein 2003 -Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer_ a phas  :LOAD Full PDF

  • CAMPBELL_1994  :LOAD Full PDF

  • Chaffer2006-PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma.  :LOAD Full PDF

  • Chang 2011 – Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus  :LOAD Full PDF

  • Chappel 1992-Review and Bio Risk of Sodium Sacc  :LOAD Full PDF

  • Charbonnel et al 2004 – ProActive  :LOAD Full PDF

  • CHENG 2002  :LOAD Full PDF

  • CHOPRA_2008  :LOAD Full PDF

  • Clay 2001 – Magnitude of PPARy Activation  :LOAD Full PDF

  • Clay 2002- 15-Deoxy prostaglandin J -induced apoptosis does not require PPAR in breast cancer cells  :LOAD Full PDF

  • Cohen 2005-Effects of PPAR and Combined Agonists on the Urinary Tract of Rats and Other Species  :LOAD Full PDF

  • Cohen1998-Urinary Bladder Carcinogenesis  :LOAD Full PDF

  • DeFronzo-NEJM-Pioglitazone for diabetes prevention in impaired glucose tolerance.  :LOAD Full PDF

  • DeFronzo2011-SuppAppendix  :LOAD Full PDF

  • DEFRONZO_2005  :LOAD Full PDF

  • DIMIC_2009  :LOAD Full PDF

  • DOMINICK 2006  :LOAD Full PDF

  • Dormandy et al 2005 – Secondary prevention of macrovascular events in patients with type 2 dm in the PROactive study  :LOAD Full PDF

  • Dormandy et al 2009 – Safety and tolerability of pioglitazone in high risk patients with type 2 DM  :LOAD Full PDF

  • EGEROD_2009  :LOAD Full PDF

  • El-Hage PPAR Slideshow  :LOAD Full PDF

  • Fauconnet2002-Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells  :LOAD Full PDF

  • Ferrara et al 2011 – Cohort study of pioglitazone and cancer incidence in patients with diabetes  :LOAD Full PDF

  • France Study – French Version  :LOAD Full PDF

  • Freedman 2011-Smoking and bladder cancer  :LOAD Full PDF

  • French Actos Study  :LOAD Full PDF

  • Friedland2012- The Cardiovascular Effects of Peroxisome Proliferator-Activated Receptor Agonists  :LOAD Full PDF

  • GARBER_2003  :LOAD Full PDF

  • Gardner_2005- Activation of Mitogen-Activated Protein Kinases by Peroxisome Proliferator-Activated Receptor Ligands_ An Example of Nongenomic Signaling  :LOAD Full PDF

  • GERICH_2005  :LOAD Full PDF

  • Giovannucci 2010 – Diabetes and Cancer A Consensus Report  :LOAD Full PDF

  • Goldstein 2006 -Lancet-PROactive Study  :LOAD Full PDF

  • GoldsteinMR-July2011-NEJM-Pioglitazone for diabetes prevention.  :LOAD Full PDF

  • GOLDSTEIN_2007  :LOAD Full PDF

  • Govindan2012-Pioglitazone in Clinical Practice_Where are we now  :LOAD Full PDF

  • Govindarajan 2007-Thiazolidinediones and the Risk of Lung_ Prostate_ and Colon Cancer in Patients With Diabetes  :LOAD Full PDF

  • Guan et all 1999 – Expression of PPAR y in human transitional bladder cancer and role in cell death  :LOAD Full PDF

  • Harris 2008  :LOAD Full PDF

  • HAYDEN_1994  :LOAD Full PDF

  • Hillaire-Buys 2011 – Pioglitazone and Bladder Cancer  :LOAD Full PDF

  • Holmang1995-TaT1 prognosis  :LOAD Full PDF

  • ILIADIS_2007  :LOAD Full PDF

  • INZUCCHI_SUMMARY OF ALL OADs  :LOAD Full PDF

  • JADZINSKY_2009  :LOAD Full PDF

  • Jiang2012-Cigarette smoking and subtypes of bladder cancer  :LOAD Full PDF

  • Kaku 2011-Pharmacotherapy of diabetes and cancer risk  :LOAD Full PDF

  • Kermani 2003  :LOAD Full PDF

  • Kiriluk2012-Bladder Cancer Risk from Occupational and Environmental Exposures  :LOAD Full PDF

  • Koeffler 2003-Peroxisome Proliferator-activated Receptor and Cancers  :LOAD Full PDF

  • Koro 2007 – Cancer risks in thiazolidinedione users compared to other anti-diabetic agents  :LOAD Full PDF

  • Kuper2002-Tobacco use and cancer causation- association by type  :LOAD Full PDF

  • Larsson2006-Diabetes Mellitus and Risk of Bladder Cancer_Meta-Analysis  :LOAD Full PDF

  • Lewis et al 2011 – Risk of bladder cancer among diabetes patients treated with pioglitazone  :LOAD Full PDF

  • Lewis-Risk of Bladder Cancer Among Diabetic Patients Treated with Pioglitazone  :LOAD Full PDF

  • LOBBAN_1998  :LOAD Full PDF

  • LONG_2008  :LOAD Full PDF

  • Lubet2008-Rosiglitazone, a PPAR gamma agonist_Potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers  :LOAD Full PDF

  • Mackenzie2010-Diabetes+Bladder Cancer  :LOAD Full PDF

  • Mannucci 2009 – Prevention of cardiovascular disease through glycemic control in type 2 diabetes_ a meta-analysis of randomized clinical trials  :LOAD Full PDF

  • Nakashiro2001-Role of PPAR and its ligands in non-bneoplastic and neoplastic human urothelial cells  :LOAD Full PDF

  • Nesto 2004  :LOAD Full PDF

  • Nesto 2012  :LOAD Full PDF

  • Neumann 2012 – Pioglitazone and risk of bladder cancer among diabetic patients in France__A population-based cohort study.  :LOAD Full PDF

  • Ohta 2001-Ligands for Peroxisome Proliferator-Activated Receptor Inhibit Growth and Induce Apoptosis of Human Papillary Thyroid Carcinoma Cells  :LOAD Full PDF

  • Oleksiewicz 2008 – Rat Urinary Bladder Carcinogenesis by Dual-Acting PPAR Agonists  :LOAD Full PDF

  • Oleksiewicz_2005  :LOAD Full PDF

  • Ondrey 2009 – Peroxisome Proliferator-Activated Receptor Pathway_Targeting in Carcinogenesis Implications for Chemoprevention  :LOAD Full PDF

  • Palakurthi 2001- Anticancer Effects of Thiazolidinediones Are Independent of Peroxisome Proliferator-activated Receptor and Mediated by Inhibition of Translation Initiation  :LOAD Full PDF

  • Panigrahy 2005-PPAR as a Therapeutic Target for Tumor Angiogenesis and Metastasis  :LOAD Full PDF

  • PAVO_2003  :LOAD Full PDF

  • Peters 2012- The Role of PPARs in carcinogenesis and chemoprevention  :LOAD Full PDF

  • Piccinni 2011-Assessing the Association ofPioglitazone Use and Bladder CancerThrough Drug Adverse Event Reporting  :LOAD Full PDF

  • RAMACHANDRAN_2004  :LOAD Full PDF

  • Ramos-Nino 2007 – Association between cancer prevalence and use of thiazolidinediones_Results from the Vermont Diabetes Information System  :LOAD Full PDF

  • Rubenstrunk 2007 -Safety issues and prospects for future generations of PPAR modulators  :LOAD Full PDF

  • Ryder & Dormandy 2011 – Comment  :LOAD Full PDF

  • Sato et al. 2011 – Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats  :LOAD Full PDF

  • SCHERNTHANER_2004  :LOAD Full PDF

  • Stephenson2011-JAMA-Diabetes drug may be associated with increase in risk of bladder cancer  :LOAD Full PDF

  • Strope2007-The Causal Role of Cigarette Smoking in Bladder Cancer Initiation  :LOAD Full PDF

  • Suzuki2010-Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat  :LOAD Full PDF

  • Tannehill-Gregg2007 – Rodent Carcinogenicity Profile of The Antidiabetic Dual PPAR and Agonist Muraglitazar  :LOAD Full PDF

  • Tolman 2004- Narrative Review-Hepatobiliary Disease in Type 2 Diabetes Mellitus  :LOAD Full PDF

  • Tolman 2009 – Liver Safety in Patients with Type 2 Diabetes Treated with Pioglitazone  :LOAD Full PDF

  • Tseng 2011 – Diabetes and Risk of Bladder Cancer  :LOAD Full PDF

  • Tseng 2011 – Pioglitazone and Bladder Cancer  :LOAD Full PDF

  • Tseng2012-Pioglitazone and bladder cancer in human studies_ Is it diabetes itself diabetes drugs flawed analyses or different ethnicities  :LOAD Full PDF

  • Wooltorton 2002  :LOAD Full PDF

  • WYNDER_1977  :LOAD Full PDF

  • Yang 2011 – Comment-analyses using time-dependent pioglitazone usage in Cox models may lead to wrong conclusions about its association with cancer  :LOAD Full PDF

  • Ye2012-Challenges in Drug Discovery for Thiazolidinedione Substitute  :LOAD Full PDF

  • Yoshimura et al 2003 – Expression of PPARs in Human Urinary Bladder Carcinoma  :LOAD Full PDF

  • Zeegers2000-Smoking and Bladder Cancer- Meta-Analysis  :LOAD Full PDF

    Zeegers2000-Smoking and Bladder Cancer- Meta-Analysis DESC